PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium (ASCO GU) to be held from January 25-27 in San Francisco, California, highlighting the company’s progress in making long-term survival outcomes a possibility for more patients with genitourinary cancers, as well as showcasing potential new options and therapeutic platforms that may transform treatment paradigms across tu ...

Bristol Myers Squibb (BMY) closed the most recent trading day at $50, moving -0.62% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.37%. Elsewhere, the Dow saw a downswing of 0.62%, while the tech-heavy Nasdaq depreciated by 0.19%.The biopharmaceutical company's shares have seen a decrease of 2.01% over the last month, not keeping up with the Medical sector's gain of 4.61% and the S&P 500's gain of 1.56%.The investment community will be paying close attent ...

BlackJack3D Yet another cheap Big Pharma stock Having recently written about the cratered pharma stock and value opportunity in Pfizer (PFE), charting the big pharma sell-offs, reveals a nearly as strong downtrend in Bristol-Myers Squibb (NYSE:BMY). The company is in a similar phase of R&D cycling and acquisitions to fill its next cycle of drugs for the next decade. Bristol Myers does not have the stigma around it from being a vaccine producer during COVID-19, but they also have their issues to reckon w ...

DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: PEAK) (“Healthpeak”), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced that it has formed a new strategic joint venture with Breakthrough Properties (“Breakthrough”) through a sale of a 65% interest in Healthpeak’s fully leased Callan Ridge lab campus in the Torrey Pines submarket of San Diego. The formation of the 65% Breakthrough / 35% Healthpeak joint venture values Callan Ridge at ...

As 2022 came to a close, investors were skeptical – to say the least. As inflation soared to 40-year highs, war broke out in Europe, a regional banking crisis gained steam and tech stocks got hammered, few Wall Street “experts” or talking heads predicted that stocks would have the bullish year they had. However, savvy investors have a way of looking past short-term gyrations in the stock market and understanding the context. While the future remains unwritten, if we look at a long-term chart of the S&P 500 ...

PM Images I have been on the hunt for value in the early days of 2024. One of my investment premises for the year is that a broad market rally will occur, and it will be led by several sectors that underperformed the market in 2023. I also think some profits from the 2023 bull market will be taken, and they will be allocated toward value in addition to capital flowing in from the sidelines trying to front-run a Fed pivot. Recently, I started a much larger position in Pfizer (PFE) outside of my Dividend ...

In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.28, marking a -0.98% move from the previous day. This change lagged the S&P 500's 0.15% loss on the day. On the other hand, the Dow registered a loss of 0.42%, and the technology-centric Nasdaq increased by 0.09%.The the stock of biopharmaceutical company has risen by 1.37% in the past month, lagging the Medical sector's gain of 6.58% and the S&P 500's gain of 3.5%.The upcoming earnings release of Bristol Myers Squibb will be of great i ...

Bristol-Myers Squibb CEO Chris Boerner detailed the pharmaceutical giant's bundle of recent acquisitions in a Monday interview with CNBC's Jim Cramer, and indicated the company is in a transformative stage."We are writing the next chapter of this company," Boerner said. "And we've got real financial strength that has enabled us to go and actually bring innovation in to the company from outside. And that's what we've done with these most recent deals."Bristol-Myers Squibb announced three multi-billion-dollar ...

Bristol-Myers Squibb Company (NYSE:BMY) J.P. Morgan 42nd Annual Healthcare Conference Call January 8, 2024 10:30 AM ET Company Participants Chris Boerner - Chief Executive Officer Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning, everybody. I'm Chris Schott at JPMorgan. It's great to see everybody back in person again this year for second year in a row. It's my pleasure this morning, though, to be introducing Bristol-Myers to again kick off the JPMorgan Healthcare Conference. F ...

Bristol-Myers Squibb Company (NYSE:BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference January 4, 2024 11:00 AM ET Company Participants Adam Lenkowsky - CCO Conference Call Participants Chris Shibutani - Goldman Sachs Operator Hey, it’s the start of the year. Welcome to 2024. Anyway, my name is Chris Shibutani. I'm a member of the Goldman Sachs healthcare team. We are deeply grateful for the teams that were able to join us for this conference this very early date this year, and obviously, the point ...